Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS).
Bolek H, Yazgan SC, Ceylan F, Esteban-Villarrubia J, Arslan C, Kuş T, Tural D, Sendur MAN, Kucuk NO, Çıngı Özdemir E, Castro E, Yekedüz E, Ürün Y. Bolek H, et al. Among authors: sendur man. Eur J Cancer. 2025 Jan 9;217:115226. doi: 10.1016/j.ejca.2025.115226. Online ahead of print. Eur J Cancer. 2025. PMID: 39813762
Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC).
Bolek H, Kuzu OF, Sertesen Camoz E, Sim S, Sekmek S, Karakas H, Isık S, Günaltılı M, Akkus AF, Tural D, Arslan C, Goksu SS, Sever ON, Karadurmus N, Karacin C, Sendur MAN, Yekedüz E, Urun Y. Bolek H, et al. Among authors: sendur man. Clin Transl Oncol. 2025 Jan 15. doi: 10.1007/s12094-024-03813-w. Online ahead of print. Clin Transl Oncol. 2025. PMID: 39812937
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study.
Kahraman S, Hizal M, Demirel BC, Guven DC, Gumusay O, Uluc BO, Bayram E, Gulbagci B, Yasar A, Davarci SE, Mocan EE, Acar O, Isik D, Aydin E, Karakas Y, Ozcelik M, Keser M, Okutur SK, Eren O, Menekse S, Aydin D, Yilmaz F, Dogan O, Ozkanli G, Yucel H, Sunar V, Aykan MB, Ozdemir O, Duman BB, Keskinkilic M, Sakalar T, Inal A, Karaoglanoglu M, Aksoy A, Er MM, Turhal NS, Kalkan NO, Sendur MAN. Kahraman S, et al. Among authors: sendur man. BMC Cancer. 2024 Dec 30;24(1):1592. doi: 10.1186/s12885-024-13357-5. BMC Cancer. 2024. PMID: 39736618 Free PMC article.
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study.
Sekmek S, Ozsan Çelebi SN, Bayram D, Erol C, Kos FT, Sendur MAN, Altıntas YE, Tuylu T, Yildirim S, Biter S, Kıdı MM, Bayram E, Majidova N, Bayoglu IV, Atak M, Baskurt K, Akbas S, Alkan A, Bayramgil A, Aslan F, Sahin E, Balcik OY, Bayhan AZ, Saray S, Arpaci E, Ergun Y. Sekmek S, et al. Among authors: sendur man. Sci Rep. 2024 Nov 30;14(1):29785. doi: 10.1038/s41598-024-81371-5. Sci Rep. 2024. PMID: 39616250 Free PMC article.
Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes.
Ozbay MF, Harputluoglu H, Karaca M, Tekin O, Şendur MAN, Kaplan MA, Sahin B, Geredeli C, Teker F, Tural D, Saglam S, Çil T, Bilici A, Erol C, Kalkan Z, Bayram E, Selvi O, Gültürk İ, Göksu SS, Tatlı AM. Ozbay MF, et al. Among authors: sendur man. Cancers (Basel). 2024 Nov 20;16(22):3880. doi: 10.3390/cancers16223880. Cancers (Basel). 2024. PMID: 39594835 Free PMC article.
Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial.
Mamtani R, Matsubara N, Pino AM, Herranz UA, Şendur MAN, Gravis G, Huillard O, Lee HJ, Gafanov R, Joly F, Bedke J, Sella A, Chang YH, Imai K, Moreno BH, Xu JZ, Alva A, Powles T. Mamtani R, et al. Among authors: sendur man. Clin Genitourin Cancer. 2024 Oct 28;23(1):102248. doi: 10.1016/j.clgc.2024.102248. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39579409 Free article.
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Gunduz S, Mamtani R, Yu EY, Montesa Pino A, Anido U, Sendur MAN, Gravis G, Révész J, Kostorov V, Huillard O, Ma J, Rajasagi M, Vajdi A, Lunceford J, Cristescu R, Imai K, Homet Moreno B, Matsubara N. Fléchon A, et al. Among authors: sendur man. Clin Cancer Res. 2024 Dec 2;30(23):5353-5364. doi: 10.1158/1078-0432.CCR-23-3518. Clin Cancer Res. 2024. PMID: 39475359 Free PMC article. Clinical Trial.
Clinical features and prognostic factors in thymoma and thymic carcinoma.
Bayram D, Sekmek S, Kayaalp M, Bardakçı M, Hafızoğlu E, Uçar G, Algin E, Bal O, Civelek B, Şendur MAN, Kos FT, Uncu D. Bayram D, et al. Among authors: sendur man. Indian J Thorac Cardiovasc Surg. 2024 Nov;40(6):660-668. doi: 10.1007/s12055-024-01741-6. Epub 2024 May 14. Indian J Thorac Cardiovasc Surg. 2024. PMID: 39416339
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy.
Ilhan Y, Ucar G, Baser MN, Guzel HG, Efil SC, Demir B, Ercan Uzundal D, Karacelik T, Sever N, Balcik OY, Arvas H, Karadag I, Kadioglu A, Ekinci ÖB, Karacin C, Urakci Z, Kostek O, Karakurt Eryilmaz M, Yazici O, Sendur MAN, Ozturk B, Uncu D, Ergun Y. Ilhan Y, et al. Among authors: sendur man. Expert Opin Pharmacother. 2024 Aug;25(11):1555-1563. doi: 10.1080/14656566.2024.2391007. Epub 2024 Aug 11. Expert Opin Pharmacother. 2024. PMID: 39115275
150 results